Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Kineticos Life Sciences is a growth equity and venture capital firm founded in Raleigh, North Carolina. The firm specializes in partnering with companies in the life sciences sector, focusing on improving patient outcomes through strategic investments. Kineticos targets specialized pharmaceutical services, tools, and equipment, aiming to bridge the gap between venture and growth equity investing.
The firm has established a diverse portfolio and operates primarily in the United States. Kineticos has developed a reputation for supporting both early-stage innovators and established companies, enhancing their capabilities and market reach. Notable milestones include the launch of the Kineticos Foundry, which serves as a venture and incubation arm, and the AMR Accelerator Fund, dedicated to combating antimicrobial resistance.
Kineticos Life Sciences invests in high-growth opportunities across the life sciences ecosystem. Their investment strategy encompasses several sectors, including specialized pharmaceutical services, oncology, neurodegenerative diseases, rare diseases, and antimicrobial resistance (AMR). The firm targets early-stage innovators and companies at various stages of development, primarily within the United States.
The firm’s investment stages range from pre-seed to growth equity, allowing them to engage with companies at different points in their lifecycle. Kineticos aims to support transformative technologies that address significant health challenges and improve patient care. Their focus on operator-led investing leverages deep scientific expertise across multiple therapeutic areas and molecule types, enhancing their ability to drive organic growth and strategic acquisitions.
Kineticos Life Sciences has built a diverse portfolio that includes several notable companies:
This portfolio reflects Kineticos' commitment to investing in companies that are at the forefront of addressing critical health challenges.
Shailesh Maingi: Founder and Managing Partner at Kineticos Life Sciences, Shailesh has extensive experience in the life sciences sector, having led multiple successful investments and exits.
Frank Lis: General Partner, Frank brings a wealth of knowledge in venture capital and operational expertise in the life sciences industry.
Keith Capecci: Principal at Kineticos, Keith focuses on identifying and evaluating investment opportunities within the life sciences sector.
Mark Bamforth: KAMRA I Investment Committee Member, Mark has a strong background in biopharmaceuticals and has been involved in numerous successful ventures.
Richard Snyder, PhD: KAMRA I Investment Committee Member, Richard is an expert in drug development and has a significant track record in the pharmaceutical industry.
Dilán Rivera: Senior Analyst, Dilán supports the investment team with market research and analysis, contributing to the firm's investment decisions.
To pitch Kineticos Life Sciences, founders should use the contact form available on their website at kineticos.com/contact-us. It is important to include a comprehensive deck that outlines the business model, market analysis, and team qualifications. Kineticos appreciates detailed information that demonstrates the startup's potential for growth and innovation.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review of the pitch.
On January 8, 2026, Kineticos Life Sciences announced positive Phase 2 trial results for EnteroBiotix's EBX-102-02, a potential first-in-class microbiome therapy for irritable bowel syndrome. This highlights Kineticos' ongoing engagement with its portfolio companies and their commitment to advancing innovative health solutions.
Additionally, Kineticos continues to expand its portfolio, focusing on investments that align with their mission to improve patient outcomes through strategic partnerships in the life sciences sector.
What are Kineticos Life Sciences' investment criteria?
Kineticos focuses on high-growth opportunities within the life sciences sector, particularly in specialized pharmaceutical services, oncology, neurodegenerative diseases, rare diseases, and antimicrobial resistance. They invest across various stages, from pre-seed to growth equity.
How can I apply or pitch to Kineticos?
Founders can pitch to Kineticos through their official website's contact page at kineticos.com/contact-us. It is advisable to include a detailed business plan and information about the team and market opportunity.
What makes Kineticos Life Sciences different from other investors?
Kineticos combines operator-led investing with deep scientific expertise across multiple therapeutic areas. This approach allows them to provide tailored support to portfolio companies, enhancing their growth potential.
What is Kineticos' geographic scope?
The firm primarily invests in the United States, focusing on companies that are innovating within the life sciences sector.
What is Kineticos' post-investment involvement like?
Kineticos actively engages with its portfolio companies, providing operational support, strategic guidance, and assistance with international expansion and acquisitions.
What is the typical check size for Kineticos investments?
While specific check sizes are not disclosed, Kineticos invests across a range of stages, indicating flexibility in their funding approach depending on the company's needs and growth stage.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.